-
1 Comment
THELMA Therapeutics Co., Ltd is currently in a long term downtrend where the price is trading 9.5% below its 200 day moving average.
From a valuation standpoint, the stock is 642.5% more expensive than other stocks from the Industrials sector with a price to sales ratio of 7.0.
THELMA Therapeutics Co., Ltd's total revenue rose by 0.9% to $2B since the same quarter in the previous year.
Its net income has increased by 32.3% to $-8B since the same quarter in the previous year.
Finally, its free cash flow grew by 54.8% to $-2B since the same quarter in the previous year.
Based on the above factors, THELMA Therapeutics Co., Ltd gets an overall score of 3/5.
| ISIN | KR7015540008 |
|---|---|
| Industry | |
| Exchange | KO |
| CurrencyCode | KRW |
| Sector |
| Market Cap | 339B |
|---|---|
| Target Price | None |
| Dividend Yield | 0.0% |
| PE Ratio | None |
| Beta | 0.09 |
THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments. The company was formerly known as Medipartner Biotechnology. Co., Ltd. THELMA Therapeutics Co., Ltd. was founded in 1981 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 015540.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
